The objective of this paper is to report a case of anti-myelin-associated glycoprotein (anti-MAG) antibody neuropathy treated with zanubrutinib, offering insight into a potential therapeutic avenue for this challenging neurological disorder. A 65-year-old male initially presented with peripheral neuropathy in the lower distal extremities. Here, MAG is linked to peripheral neuropathy.